<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hegde, Muralidhar L.</style></author><author><style face="normal" font="default" size="100%">Bharathi, P.</style></author><author><style face="normal" font="default" size="100%">Suram, Anitha</style></author><author><style face="normal" font="default" size="100%">Venugopal, Chitra</style></author><author><style face="normal" font="default" size="100%">Jagannathan, Ramya</style></author><author><style face="normal" font="default" size="100%">Poddar, Pankaj</style></author><author><style face="normal" font="default" size="100%">Srinivas, Pullabhatla</style></author><author><style face="normal" font="default" size="100%">Sambamurti, Kumar</style></author><author><style face="normal" font="default" size="100%">Rao, Kosagisharaf Jagannatha</style></author><author><style face="normal" font="default" size="100%">Scancar, Janez</style></author><author><style face="normal" font="default" size="100%">Messori, Luigi</style></author><author><style face="normal" font="default" size="100%">Zecca, Luigi</style></author><author><style face="normal" font="default" size="100%">Zatta, Paolo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Challenges associated with metal chelation therapy in alzheimer's disease</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Alzheimers Disease</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Alzheimer's disease</style></keyword><keyword><style  face="normal" font="default" size="100%">clioquinol</style></keyword><keyword><style  face="normal" font="default" size="100%">cuprizone</style></keyword><keyword><style  face="normal" font="default" size="100%">metal dishomeostasis</style></keyword><keyword><style  face="normal" font="default" size="100%">metal ions</style></keyword><keyword><style  face="normal" font="default" size="100%">nanomedicine</style></keyword><keyword><style  face="normal" font="default" size="100%">Parkinson's disease</style></keyword><keyword><style  face="normal" font="default" size="100%">polyphenols</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">JUL</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">3</style></number><publisher><style face="normal" font="default" size="100%">IOS PRESS</style></publisher><pub-location><style face="normal" font="default" size="100%">NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS</style></pub-location><volume><style face="normal" font="default" size="100%">17</style></volume><pages><style face="normal" font="default" size="100%">457-468</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;A close association between brain metal dishomeostasis and the onset and/or progression of Alzheimer's disease ( AD) has been clearly established in a number of studies, although the underlying biochemical mechanisms remain obscure. This observation renders chelation therapy an attractive pharmacological option for the treatment of this disease. However, a number of requirements must be fulfilled in order to adapt chelation therapy to AD so that the term ``metal targeted strategies'' seems now more appropriate. Indeed, brain metal redistribution rather than brain metal scavenging and removal is the major goal of this type of intervention. The most recent developments in metal targeted strategies for AD will be discussed using, as useful examples, clioquinol, curcumin, and epigallocatechin, and the future perspectives will also be outlined.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><custom3><style face="normal" font="default" size="100%">Foreign</style></custom3><custom4><style face="normal" font="default" size="100%">4.261</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Paraskar, Abhimanyu S.</style></author><author><style face="normal" font="default" size="100%">Soni, Shivani</style></author><author><style face="normal" font="default" size="100%">Chin, Kenneth T.</style></author><author><style face="normal" font="default" size="100%">Chaudhuri, Padmaparna</style></author><author><style face="normal" font="default" size="100%">Muto, Katherine W.</style></author><author><style face="normal" font="default" size="100%">Berkowitz, Julia</style></author><author><style face="normal" font="default" size="100%">Handlogten, Michael W.</style></author><author><style face="normal" font="default" size="100%">Alves, Nathan J.</style></author><author><style face="normal" font="default" size="100%">Bilgicer, Basar</style></author><author><style face="normal" font="default" size="100%">Dinulescu, Daniela M.</style></author><author><style face="normal" font="default" size="100%">Mashelkar, Raghunath Anant</style></author><author><style face="normal" font="default" size="100%">Sengupta, Shiladitya</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy</style></title><secondary-title><style face="normal" font="default" size="100%">Proceedings of the National Academy of Sciences of the United States of America</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">chemotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">nanomedicine</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">JUL</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">28</style></number><publisher><style face="normal" font="default" size="100%">NATL ACAD SCIENCES</style></publisher><pub-location><style face="normal" font="default" size="100%">2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA</style></pub-location><volume><style face="normal" font="default" size="100%">107</style></volume><pages><style face="normal" font="default" size="100%">12435-12440</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Cisplatin is a first line chemotherapy for most types of cancer. However, its use is dose-limited due to severe nephrotoxicity. Here we report the rational engineering of a novel nanoplatinate inspired by the mechanisms underlying cisplatin bioactivation. We engineered a novel polymer, glucosamine-functionalized polyisobutylene-maleic acid, where platinum (Pt) can be complexed to the monomeric units using a monocarboxylato and an O –&amp;gt; Pt coordinate bond. We show that at a unique platinum to polymer ratio, this complex self-assembles into a nanoparticle, which releases cisplatin in a pH-dependent manner. The nanoparticles are rapidly internalized into the endolysosomal compartment of cancer cells, and exhibit an IC50 (4.25 + 0.16 mu M) comparable to that of free cisplatin (3.87 +/- 0.37 mu M), and superior to carboplatin (14.75 +/- 0.38 mu M). The nanoparticles exhibited significantly improved antitumor efficacy in terms of tumor growth delay in breast and lung cancers and tumor regression in a K-ras(LSL/+)/Pten(fl/fl) ovarian cancer model. Furthermore, the nanoparticle treatment resulted in reduced systemic and nephrotoxicity, validated by decreased biodistribution of platinum to the kidney as quantified using inductively coupled plasma spectroscopy. Given the universal need for a better platinate, we anticipate this coupling of nanotechnology and structure-activity relationship to rationally reengineer cisplatin could have a major impact globally in the clinical treatment of cancer.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">28</style></issue><custom3><style face="normal" font="default" size="100%">Foreign</style></custom3><custom4><style face="normal" font="default" size="100%">9.423</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sengupta, Poulomi</style></author><author><style face="normal" font="default" size="100%">Basu, Sudipta</style></author><author><style face="normal" font="default" size="100%">Soni, Shivani</style></author><author><style face="normal" font="default" size="100%">Pandey, Ambarish</style></author><author><style face="normal" font="default" size="100%">Roy, Bhaskar</style></author><author><style face="normal" font="default" size="100%">Oh, Michael S.</style></author><author><style face="normal" font="default" size="100%">Chin, Kenneth T.</style></author><author><style face="normal" font="default" size="100%">Paraskar, Abhimanyu S.</style></author><author><style face="normal" font="default" size="100%">Sarangi, Sasmit</style></author><author><style face="normal" font="default" size="100%">Connor, Yamicia</style></author><author><style face="normal" font="default" size="100%">Sabbisetti, Venkata S.</style></author><author><style face="normal" font="default" size="100%">Kopparam, Jawahar</style></author><author><style face="normal" font="default" size="100%">Kulkarni, Ashish</style></author><author><style face="normal" font="default" size="100%">Muto, Katherine</style></author><author><style face="normal" font="default" size="100%">Amarasiriwardena, Chitra</style></author><author><style face="normal" font="default" size="100%">Jayawardene, Innocent</style></author><author><style face="normal" font="default" size="100%">Lupoli, Nicola</style></author><author><style face="normal" font="default" size="100%">Dinulescu, Daniela M.</style></author><author><style face="normal" font="default" size="100%">Bonventre, Joseph V.</style></author><author><style face="normal" font="default" size="100%">Mashelkar, Raghunath Anant</style></author><author><style face="normal" font="default" size="100%">Sengupta, Shiladitya</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity</style></title><secondary-title><style face="normal" font="default" size="100%">Proceedings of the National Academy of Sciences of the United States of America</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">chemotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">nanomedicine</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">JUL</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">28</style></number><publisher><style face="normal" font="default" size="100%">NATL ACAD SCIENCES</style></publisher><pub-location><style face="normal" font="default" size="100%">2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA</style></pub-location><volume><style face="normal" font="default" size="100%">109</style></volume><pages><style face="normal" font="default" size="100%">11294-11299</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Nanoscale drug delivery vehicles have been harnessed extensively as carriers for cancer chemotherapeutics. However, traditional pharmaceutical approaches for nanoformulation have been a challenge with molecules that exhibit incompatible physicochemical properties, such as platinum-based chemotherapeutics. Here we propose a paradigm based on rational design of active molecules that facilitate supramolecular assembly in the nanoscale dimension. Using cisplatin as a template, we describe the synthesis of a unique platinum (II) tethered to a cholesterol backbone via a unique monocarboxylato and O -&amp;gt; Pt coordination environment that facilitates nanoparticle assembly with a fixed ratio of phosphatidylcholine and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine- N-[amino (polyethylene glycol)-2000]. The nanoparticles formed exhibit lower IC50 values compared with carboplatin or cisplatin in vitro, and are active in cisplatin-resistant conditions. Additionally, the nanoparticles exhibit significantly enhanced in vivo antitumor efficacy in murine 4T1 breast cancer and in K-Ras(LSL/+/)Pten(fl/fl) ovarian cancer models with decreased systemic- and nephro-toxicity. Our results indicate that integrating rational drug design and supramolecular nanochemistry can emerge as a powerful strategy for drug development. Furthermore, given that platinum-based chemotherapeutics form the frontline therapy for a broad range of cancers, the increased efficacy and toxicity profile indicate the constructed nanostructure could translate into a nextgeneration platinum-based agent in the clinics.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">28</style></issue><custom3><style face="normal" font="default" size="100%">Foreign</style></custom3><custom4><style face="normal" font="default" size="100%">10.66
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kale, Sonia</style></author><author><style face="normal" font="default" size="100%">Kale, Anup</style></author><author><style face="normal" font="default" size="100%">Gholap, Haribhau</style></author><author><style face="normal" font="default" size="100%">Rana, Abhimanyu</style></author><author><style face="normal" font="default" size="100%">Desai, Rama</style></author><author><style face="normal" font="default" size="100%">Banpurkar, Arun G.</style></author><author><style face="normal" font="default" size="100%">Ogale, Satishchandra</style></author><author><style face="normal" font="default" size="100%">Shastry, Padma</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Quantum dot bio-conjugate: as a western blot probe for highly sensitive detection of cellular proteins</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Nanoparticle Research</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Detection</style></keyword><keyword><style  face="normal" font="default" size="100%">Imaging</style></keyword><keyword><style  face="normal" font="default" size="100%">nanomedicine</style></keyword><keyword><style  face="normal" font="default" size="100%">quantum dot</style></keyword><keyword><style  face="normal" font="default" size="100%">Rapid</style></keyword><keyword><style  face="normal" font="default" size="100%">sensors</style></keyword><keyword><style  face="normal" font="default" size="100%">Western blot</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">MAR</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">3</style></number><publisher><style face="normal" font="default" size="100%">SPRINGER</style></publisher><pub-location><style face="normal" font="default" size="100%">VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS</style></pub-location><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">732</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;In the present study, we report a quantum dot (QD)-tailored western blot analysis for a sensitive, rapid and flexible detection of the nuclear and cytoplasmic proteins. Highly luminescent CdTe and (CdTe) ZnS QDs are synthesized by aqueous method. High resolution transmission electron microscopy, Raman spectroscopy, fourier transform infrared spectroscopy, fluorescence spectroscopy and X-ray diffraction are used to characterize the properties of the quantum dots. The QDs are functionalized with antibodies of prostate apoptosis response-4 (Par-4), poly(ADP-ribose) polymerases and beta actin to specifically bind with the proteins localized in the nucleus and cytoplasm of the cells, respectively. The QD-conjugated antibodies are used to overcome the limitations of conventional western blot technique. The sensitivity and rapidity of protein detection in QD-based approach is very high, with detection limits up to 10 pg of protein. In addition, these labels provide the capability of enhanced identification and localization of marker proteins in intact cells by confocal laser scanning microscopy.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><custom3><style face="normal" font="default" size="100%">Foreign</style></custom3><custom4><style face="normal" font="default" size="100%">2.175
</style></custom4></record></records></xml>